VEGFA and hepatocellular carcinoma: Based on this debate between previous studies, we aimed to evaluate the potential risk of developing de novo HCC in HCV patients treated with DAAs by measuring VEGF and AFP levels at different points in time during and 12 weeks after treatment of HCV.